Arezou Khosroshahi, MD
Enriched profileProfessor of Medicine · Emory University School of Medicine
Arezou Khosroshahi is Professor of Medicine at Emory University School of Medicine. OpenAlex indexes 107 publications with 13,282 citations (h-index 37); ClinicalTrials.gov lists 2 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Arezou Khosroshahi, MD, is Professor of Medicine at Emory University School of Medicine, Division of Rheumatology (Department of Medicine). The public record shows 107 publications with 13,282 citations (h-index 37), centered on Rheumatology/Immunology. It also documents an investigator role on 2 registered clinical trials, industry payments reported by 5 companies.
- Most recent indexed publication: 2026 · medRxiv
- Top research focus: Rheumatology/Immunology
- 2 registered trials on ClinicalTrials.gov
- Open Payments reporting from 5 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 2 registered studies on ClinicalTrials.gov. The most recent:
- Lupus Landmark Study: A Prospective Registry and Biorepository
Sponsor: Lupus Research Alliance
- Rituximab in IgG4-RD: A Phase 1-2 Trial
Sponsor: Massachusetts General Hospital
Industry payments
Updated 27 Aug 2026
5 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year20259 payments$12,356openpaymentsdata.cms.gov ↗
- Amgen Inc.Program year20257 payments
- Amgen Inc.Program year202412 payments$26,141openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Antiparasitic
29.5%Antimalarial29.5%Hydroxychloroquine Sulfate100%Part D≥65 patientsMetabolism & gastrointestinal
26.7%Corticosteroid24.8%Prednisone100%Part D≥62 patientsProton pump inhibitor1.9%Pantoprazole Sodium100%Part D<11 patientsCancer & immunology
19.4%Folate Analog Metabolic Inhibitor6.8%Methotrexate100%Part D≥15 patientsPurine Antimetabolite4.7%Azathioprine100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Multiplicative Impact of Adverse Social Determinants of Health on Outcomes in Lupus Nephritis: A Meta-analysis and Systematic Review.
Arthritis care & research
Meta-analysis2024 - Efficacy and Safety of Inebilizumab in IgG4-Related Disease: Protocol for a Randomized Controlled Trial.
Rheumatology and therapy
Article2023 - Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial.
Arthritis & rheumatology (Hoboken, N.J.)
Clinical Trial2023 - Performance of Modified ALMS and BLISS Criteria with Standard of Care Treatment in Two US Health Care Systems.
Arthritis care & research
Article2023
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- LinkedIn
linkedin.com/in/arezou-khosroshahi-58b54132
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Arezou-Khosroshahi
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - Doximity
doximity.com/pub/arezou-khosroshahi-md-836df5f2
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Instagram
instagram.com/p/DDucO21zlKK
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - Instagram
instagram.com/p/DId9esLu3wF
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com ↗ - Other
emorydailypulse.com/2015/09/28/arezou-khosroshahi-md-featured-in-the-rheumatologist-for-igg4-study
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →emorydailypulse.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
Editorial & leadership roles
journal and society appointments- Associate Program Director
Rheumatology Fellowship, Emory University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - Co-director
First and Second International Symposiums on IgG4-Related Disease; primary author …
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →acrjournals.onlinelibrary.wiley.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providers.emoryhealthcare.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Media & interviews
press, podcasts and appearances- Podcast interview: Med Journal 360 Spotlight Series
"Dr. Arezou Khosroshahi on steroid-sparing treatment for IgG4-related disease"
2025verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medjournal360.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Arshed Quyyumi, MD
Emory University School of Medicine
Guillermo Umpierrez, MD
Emory University School of Medicine
Stewart Factor, DO
Emory University School of Medicine
Nadine Rouphael, MD
Emory University School of Medicine